Promising leukemia combo trial pulled before it began
NCT ID NCT07052994
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- revumenib (a targeted drug) combined with chemotherapy drugs (cytarabine, daunorubicin, gemtuzumab ozogamicin)
- What this could lead to
- If it had worked, this could have pointed toward a new treatment option for children with certain types of acute leukemia.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no results are available. The combination may have caused severe side effects or failed to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?